Evidence map›Paper›PMID 24626482›Full record

ArticlePloS one2014

DNA and protein co-immunization improves the magnitude and longevity of humoral immune responses in macaques.

Rashmi Jalah, Viraj Kulkarni, Vainav Patel, Margherita Rosati, Candido Alicea, Jenifer Bear, Lei Yu, Yongjun Guan, Xiaoying Shen, Georgia D Tomaras and 12 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Controlling timing and location in vaccines.Advanced drug delivery reviews · 2020
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Recent advancements in single dose slow-release devices for prophylactic vaccines.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023
    Review
  9. DNA Vaccines in Pigs: From Immunization to Antigen Identification.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Heterologous Prime-Boost Vaccination EnhancesFrontiers in microbiology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 9 institutions in 1 country.

Rashmi JalahHuman Retrovirus Pathogenesis Section, National Cancer Institute, Frederick, Maryland, United States of America.
Viraj KulkarniHuman Retrovirus Pathogenesis Section, National Cancer Institute, Frederick, Maryland, United States of America.
Vainav PatelHuman Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America.
Margherita RosatiHuman Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America.
Candido AliceaHuman Retrovirus Pathogenesis Section, National Cancer Institute, Frederick, Maryland, United States of America.
Jenifer BearHuman Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America.
Lei YuInstitute of Human Virology, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Yongjun GuanInstitute of Human Virology, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Xiaoying ShenDuke Human Vaccine Institute and Departments of Surgery and Immunology, Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, United States of America.
Georgia D TomarasDuke Human Vaccine Institute and Departments of Surgery and Immunology, Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, United States of America.
Celia LaBrancheDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America.
David C MontefioriDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America.
Rajasekhar PrattipatiPublic Health Research Institute, University of Medicine and Dentistry of New Jersey, Newark, New Jersey, United States of America.
Abraham PinterPublic Health Research Institute, University of Medicine and Dentistry of New Jersey, Newark, New Jersey, United States of America.
Julian BessAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
Jeffrey D LifsonAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
Steven G ReedInfectious Disease Research Institute, Seattle, Washington, United States of America.
Niranjan Y SardesaiInovio Pharmaceuticals, Inc., Blue Bell, Pennsylvania, United States of America.
David J VenzonBiostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.
Antonio ValentinHuman Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America.
George N PavlakisHuman Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America.
Barbara K FelberHuman Retrovirus Pathogenesis Section, National Cancer Institute, Frederick, Maryland, United States of America.
Center for Cancer Research · USNational Cancer Institute · USDuke Medical Center · USDuke University · USUniversity of Maryland, Baltimore · USFrederick National Laboratory for Cancer Research · USInfectious Disease Research Institute · USInovio Pharmaceuticals (United States) · USLeidos (United States) · US

Funding

Prevention of AIDSZIABC010350 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FELBER, BARBARA K · 2009 to 2025
$30.0M
Immunotherapeutic Approaches for AIDSZIABC010749 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PAVLAKIS, GEORGE N. · 2009 to 2022
$21.6M
Optimizing protective vaccine targets in the V1/V2 domain of HIV-1 gp120R01AI102718 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI PINTER, ABRAHAM · 2012 to 2015
$2.7M
CCR NIH HHS HHSN261200800001CIntramural NIH HHSNCI NIH HHS HHSN261200800001ENIAID NIH HHS R01 AI102718NIAID NIH HHS R01AI102718PHS HHS HHSN27201100016C
6 · The paper itself

Abstract

We tested the concept of combining DNA with protein to improve anti-HIV Env systemic and mucosal humoral immune responses. Rhesus macaques were vaccinated with DNA, DNA&protein co-immunization or DNA prime followed by protein boost, and the magnitude and mucosal dissemination of the antibody responses were monitored in both plasma and mucosal secretions. We achieved induction of robust humoral responses by optimized DNA vaccination delivered by in vivo electroporation. These responses were greatly increased upon administration of a protein boost. Importantly, a co-immunization regimen of DNA&protein injected in the same muscle at the same time induced the highest systemic binding and neutralizing antibodies to homologous or heterologous Env as well as the highest Env-specific IgG in saliva. Inclusion of protein in the vaccine resulted in more immunized animals with Env-specific IgG in rectal fluids. Inclusion of DNA in the vaccine significantly increased the longevity of systemic humoral immune responses, whereas protein immunization, either as the only vaccine component or as boost after DNA prime, was followed by a great decline of humoral immune responses overtime. We conclude that DNA&protein co-delivery in a simple vaccine regimen combines the strength of each vaccine component, resulting in improved magnitude, extended longevity and increased mucosal dissemination of the induced antibodies in immunized rhesus macaques.

Indexed as

Immunity, HumoralAdjuvants, ImmunologicAnimalsAntibodies, NeutralizingAntibodies, ViralDNA, ViralElectroporationFemaleGene Products, envImmunity, CellularImmunoglobulin GMacaca mulattaMaleSAIDS VaccinesSimian Immunodeficiency VirusVaccines, DNAAdjuvants, ImmunologicAntibodies, NeutralizingAntibodies, ViralDNA, ViralGene Products, envImmunoglobulin GSAIDS VaccinesVaccines, DNA

Identifiers

PMID24626482
PMCPMC3953433
OpenAlexW1991518158

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.